COBENFY

Growth

xanomeline and trospium chloride

NDAORALCAPSULE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

Cholinergic Muscarinic Agonists

Pharmacologic Class:

Cholinergic Muscarinic Agonist

Clinical Trials (2)

NCT07423546Phase 1/2Not Yet Recruiting

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

Started Apr 2026
12 enrolled
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder
NCT07379827N/ARecruiting

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Started Feb 2026
1,500 enrolled
Schizophrenia

Loss of Exclusivity

LOE Date
Sep 27, 2039
165 months away
Patent Expiry
Sep 27, 2039
Exclusivity Expiry
Sep 26, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
10238643
Jul 21, 2030
Product
10265311
Jul 21, 2030
U-3513
10369143
Jul 21, 2030
U-3513
10369144
Jul 21, 2030
Product
U-3513
10695339
Jul 21, 2030
U-3513